Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 Genitourinary Cancers Symposium /
PROSPER RCC study of perioperative nivolumab for renal cell carcinoma - future trial

8th - 10th Feb 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.02.18
Views: 691

Dr Lauren Harshman - Dana-Farber Cancer Institute, Boston, USA

Dr Harshman speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about the recently started PROSPER RCC study, a phase III randomised study comparing perioperative nivolumab vs. observation in patients with localised renal cell carcinoma undergoing nephrectomy. It promises to be an interesting study to watch over the next few years. 

Dr Naomi Haas also spoke with ecancer about the PROSPER study and adjuvant therapy for renal cell carcinoma here.

For more on immunotherapy in kidney cancer, read about the impact of atezolizumab and bevacizumab on mRCC here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation